Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026
Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026
Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Deals

Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices

Fineline Cube Oct 26, 2023

Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured...

Company Drug

Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment

Fineline Cube Oct 26, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression

Fineline Cube Oct 26, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...

Company Drug

Novartis’ Pluvicto Demonstrates Positive Phase III Results in mCRPC Treatment

Fineline Cube Oct 26, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has released encouraging data from a Phase III study...

Company Drug

Life Molecular Imaging and Sinotau Pharmaceutical Secure NMPA Approval for Neuraceq in China

Fineline Cube Oct 26, 2023

Germany-headquartered Life Molecular Imaging (LMI) and China-based Sinotau Pharmaceutical Group have announced that Neuraceq (florbetaben...

Company Drug

Innovent Biologics’ GFH925 on Track for Priority Review Status for NSCLC Treatment

Fineline Cube Oct 26, 2023

The Center for Drug Evaluation (CDE) has indicated that Innovent Biologics’s (HKG: 1801) Category 1...

Policy / Regulatory

CDE Releases 75th Batch of Generic Reference Preparations with Updated Specifications

Fineline Cube Oct 26, 2023

The Center for Drug Evaluation (CDE) has announced the release of the 75th batch of...

Company Drug

Zhejiang Jianfeng Receives FDA Approval for JFAN-1001 Clinical Trial in NSCLC

Fineline Cube Oct 26, 2023

Zhejiang Jianfeng Group Co., Ltd (SHA: 600668), a leading pharmaceutical company based in China, has...

Company Medical Device

MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device

Fineline Cube Oct 26, 2023

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028

Fineline Cube Oct 26, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Oct 26, 2023

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the milestone of the first patient...

Company Deals

Aiolos Bio Inc. Raises USD 245 Million in Series A Funding Led by Top Investors

Fineline Cube Oct 26, 2023

Aiolos Bio Inc., a US-based biotech company, has officially launched with the successful completion of...

Company Drug

Qilu Pharmaceutical Unveils Promising Data for QL1706 in Cervical Cancer Treatment at ESMO 2023

Fineline Cube Oct 26, 2023

China’s Qilu Pharmaceutical showcased compelling data for its combination drug QL1706 (iparomlimab and tuvonralimab) as...

Company

Medytox Shifts Strategy for China Market Entry with Next-Generation Botulinum Toxin

Fineline Cube Oct 26, 2023

Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according...

Company Medical Device

MicroPort MedBot’s Toumai Robot Gains NMPA Approval for Endoscopic Surgery

Fineline Cube Oct 26, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252), a leading medical robotics company, has announced...

Company

Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline

Fineline Cube Oct 26, 2023

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023...

Company Deals

AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development

Fineline Cube Oct 25, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...

Company Drug

EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC

Fineline Cube Oct 25, 2023

The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...

Company Drug

Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023

Fineline Cube Oct 25, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...

Company Deals Drug

AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment

Fineline Cube Oct 25, 2023

AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...

Posts pagination

1 … 451 452 453 … 663

Recent updates

  • Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China
  • Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties
  • Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304
  • CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer
  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.